Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shao-Liang Jiang, Li Li, Song-Bo Kou, Lu Hu & Jie-Hua Shi. (2023) Insight into intermolecular binding mechanism of apatinib mesylate and human alpha-1-acid glycoprotein: combined multi-spectroscopic approaches with in silico. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-12.
Read now
Read now
Zhangqiang Xiang, Xiangyu Deng, Wenfeng He, Qian Yang, Laichao Ni, Marzieh Dehghan Shasaltaneh, Mazaher Maghsoudloo, Gang Yang, Jingbo Wu, Saber Imani & Qinglian Wen. (2022) Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Annals of Medicine 54:1, pages 1357-1371.
Read now
Read now
Xiangui Meng, Hongwei Yuan, Weiquan Li, Wen Xiao & Xiaoping Zhang. (2021) Biomarker Screening and Prognostic Significance Analysis for Renal Cell Carcinoma. International Journal of General Medicine 14, pages 5255-5267.
Read now
Read now
Hongchao Zhen, Guangxin Li, Pengfei Zhao, Ying Zhang, Jing Wang, Junxian Yu & Bangwei Cao. (2020) Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. OncoTargets and Therapy 13, pages 12325-12339.
Read now
Read now
Mingting Wang, Qin Zeng, Yuan Li, Saber Imani, Danna Xie, Yinghua Li, Yunwei Han & Juan Fan. (2020) Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. Journal of Drug Targeting 28:9, pages 961-969.
Read now
Read now
Chao Chen, Shukui Qin, Zixiong Li, Xianwen Luo, Yu Zhang, Jue Zhang & Xiufeng Liu. (2019) A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix. OncoTargets and Therapy 12, pages 5805-5811.
Read now
Read now
Articles from other publishers (25)
Xing Xu & Mengjie Liang. (2023) Mechanism of Apatinib gene carried with carbon nanotube in regulating the growth and chemosensitivity of human papilloma virus through inducing AMPK/TSC2/mTOR signal pathway. Materials Express 13:7, pages 1185-1191.
Crossref
Crossref
Zheng Yang, Zheng-Ye Liu, Mourboul Ablise, Aikebaier Maimaiti, Zuohelaguli Mutalipu, Yusupuwajimu Alimujiang & Aizitiaili Aihaiti. (2023) Design, Synthesis, and Anti-Cervical Cancer and Reversal of Tumor Multidrug Resistance Activity of Novel Nitrogen-Containing Heterocyclic Chalcone Derivatives. Molecules 28:11, pages 4537.
Crossref
Crossref
Soumik Das, Achsha Babu, Tamma Medha, Gnanasambandan Ramanathan, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Reshma Murali, Sandra Kannampuzha, Abilash Valsala Gopalakrishnan, Kaviyarasi Renu, Debottam Sinha & C. George Priya Doss. (2023) Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients. Medical Oncology 40:5.
Crossref
Crossref
Hongchao Zhen, Jizheng Tian, Guangxin Li, Pengfei Zhao, Ying Zhang, Juanjuan Che & Bangwei Cao. (2023) Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis. BMC Cancer 23:1.
Crossref
Crossref
Aizhi Geng, Hailei Yang, Zhenfeng Wang & Chuanzhong Wu. (2022) Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics 47:12, pages 2264-2273.
Crossref
Crossref
Hongrui Liu, Yiqun Yu, Lu Liu, Chunyan Wang, Nan Guo, Xiaojuan Wang, Xiaoqiang Xiang & Bing Han. (2022) Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib. Frontiers in Pharmacology 13.
Crossref
Crossref
Yanyan Chi, Feng Wang, Yana Zhang, Zhengzheng Shan, Weili Tao, Yujin Lian, Dao Xin, Qingxia Fan & Yan Sun. (2022) Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma. Journal of Cellular and Molecular Medicine 26:7, pages 1905-1917.
Crossref
Crossref
Yaxing Wei, Wenjie Wu, Yanan Jiang, Hao Zhou, Yin Yu, Lili Zhao, Xiangyu Wu, Xuebo Lu, Qiang Yuan, Zitong Wang, Zigang Dong, Luyun He, Jimin Zhao & Kangdong Liu. (2021) Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4. British Journal of Cancer 126:7, pages 1037-1046.
Crossref
Crossref
Yanping Bei, Xue Chen, Quan Xu, Jiaming Lv, Jing Hu & Shaohui Yang. (2021)
Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing
JAK
/
STAT3
signaling pathway
. Drug Development Research 83:2, pages 379-388.
Crossref
Crossref
Andrew Sulaiman, Jason Chambers, Sai Charan Chilumula, Vishak Vinod, Rohith Kandunuri, Sarah McGarry & Sung Kim. (2022) At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy. Cancers 14:6, pages 1577.
Crossref
Crossref
Heming Lu, Yuying Wu, Xu Liu, Huixian Huang, Hailan Jiang, Chaohua Zhu, Yuping Man, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Xianglong Li, Junzhao Gu, Shan Deng & Ligang Xing. (2021) Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 28:9, pages 929-944.
Crossref
Crossref
Hui Yang, Min Chen, Zijie Mei, Conghua Xie, Yunfeng Zhou & Hui Qiu. (2021) Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study. Cancer Medicine 10:13, pages 4282-4290.
Crossref
Crossref
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters & Omidreza Firuzi. (2021) Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology 160, pages 103234.
Crossref
Crossref
Dongmei Chi, Baoqing Chen, Suping Guo, Kunhao Bai, Huali Ma, Yonghong Hu, Qiaoqiao Li & Yujia Zhu. (2021) Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. Aging 13:6, pages 8408-8420.
Crossref
Crossref
Zhen Yan, Yuan‑Yuan Gu, Xiao‑Di Hu, Qun Zhao, Hai‑Li Kang, Miao Wang, Wei Duan & Yin Guan. (2020) Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncology Letters 20:3, pages 3035-3045.
Crossref
Crossref
Ning Li, Ziyi Wang, Guangwen Yuan, Yangchun Sun, Rong Zhang, Xiaoguang Li, Nan Li, Jing Wang & Lingying Wu. (2020) An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. Journal of Oncology 2020, pages 1-6.
Crossref
Crossref
Wen Xiao, Ke Chen & Xiaoping Zhang. (2020) Pivotal biomarker expression and drug screening in advanced ccRCC. Clinical and Translational Medicine 10:2.
Crossref
Crossref
Xiaodan Sun, Ji Li, Yizhuo Li, Shouhan Wang & Qingchang Li. (2020) Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells. Oxidative Medicine and Cellular Longevity 2020, pages 1-19.
Crossref
Crossref
Qiufen Guo, Yawen Sun, Enqi Kong, Linli Rao, Jinlong Chen, Qian Wu, Tingting Zhang, Naifu Liu, Mingjiang Li & Li Sun. (2020) Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer. Medicine 99:11, pages e19372.
Crossref
Crossref
Nazila Fathi Maroufi, Mohammad Reza Rashidi, Vahid Vahedian, Maryam Akbarzadeh, Amir Fattahi & Mohammad Nouri. (2020) Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sciences 241, pages 117106.
Crossref
Crossref
Yong-An Song, Ting Ma, Xue-Yan Zhang, Xiang-Song Cheng, Ayobami-Matthew Olajuyin, Zhi-Fu Sun & Xiao-Ju Zhang. (2019) Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. Cancer Cell International 19:1.
Crossref
Crossref
Jinping Gu, Dan Shu, Feng Su, Yuanyuan Xie & Xianrui Liang. (2019) Analysis of metabolome changes in the HepG2 cells of apatinib treatment by using the NMR‐based metabolomics. Journal of Cellular Biochemistry 120:11, pages 19137-19146.
Crossref
Crossref
Min Han & Dongdong Sun. (2019) Rational creation and systematic analysis of cervical cancer kinase–inhibitor binding profile. Journal of Computer-Aided Molecular Design 33:7, pages 689-698.
Crossref
Crossref
Li-Xia Zhu, Qin Liu, Ya-Fang Hua, Ning Yang, Xue-Gang Zhang & Xi Ding. (2019) Systematic Profiling and Evaluation of Structure-based Kinase–Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels. Computational Biology and Chemistry 80, pages 324-332.
Crossref
Crossref
Ting Li, Shan-Bing Wang, Kai-Jian Lei, Mao-Qiong Jiang & Yu-Ming Jia. (2019) Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer. Medicine 98:4, pages e14182.
Crossref
Crossref